Literature DB >> 21354057

Common leukemia- and lymphoma-associated genetic aberrations in healthy individuals.

Jianbo Song1, Danielle Mercer, Xiaofeng Hu, Henry Liu, Marilyn M Li.   

Abstract

Leukemia- and lymphoma-associated (LLA) chromosomal rearrangements are critical in the process of tumorigenesis. These genetic alterations are also important biological markers in the diagnosis, prognosis, and treatment of hematopoietic malignant diseases. To detect the presence or absence of these genetic alterations in healthy individuals, sensitive nested RT-PCR analyses were performed on a large number of peripheral blood samples for selected markers including MLL partial tandem duplications (PTDs), BCR-ABL p190, BCR-ABL p210, MLL-AF4, AML1-ETO, PML-RARA, and CBFB-MYH11. Using nested RT-PCR, the presence of all of these selected markers was detected in healthy individuals at various prevalence rates. No correlation was observed between incidence and age except for BCR-ABL p210 fusion, the incidence of which rises with increasing age. In addition, nested RT-PCR was performed on a large cohort of umbilical cord blood samples for MLL PTD, BCR-ABL p190 and BCR-ABL p210. The results demonstrated the presence of these aberrations in cord blood from healthy neonates. To our knowledge, the presence of PML-RARA and CBFB-MYH11 in healthy individuals has not been previously described. The present study provides further evidence for the presence of LLA genetic alterations in healthy individuals and suggests that these mutations are not themselves sufficient for malignant transformation.
Copyright © 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21354057      PMCID: PMC3128552          DOI: 10.1016/j.jmoldx.2010.10.009

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  30 in total

Review 1.  Molecular insights into the Philadelphia translocation.

Authors:  N Heisterkamp; J Groffen
Journal:  Hematol Pathol       Date:  1991

2.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

3.  Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.

Authors:  M A Caligiuri; M P Strout; D Lawrence; D C Arthur; M R Baer; F Yu; S Knuutila; K Mrózek; A R Oberkircher; G Marcucci; A de la Chapelle; E Elonen; A W Block; P N Rao; G P Herzig; B L Powell; T Ruutu; C A Schiffer; C D Bloomfield
Journal:  Cancer Res       Date:  1998-01-01       Impact factor: 12.701

4.  Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors.

Authors:  S Schnittger; B Wörmann; W Hiddemann; F Griesinger
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113

5.  Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations.

Authors:  M A Caligiuri; S A Schichman; M P Strout; K Mrózek; M R Baer; S R Frankel; M Barcos; G P Herzig; C M Croce; C D Bloomfield
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

6.  Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation.

Authors:  A Biondi; A Rambaldi; V Rossi; L Elia; C Caslini; G Basso; R Battista; T Barbui; F Mandelli; G Masera
Journal:  Blood       Date:  1993-11-15       Impact factor: 22.113

7.  Clinical and hematologic characteristics in acute leukemia with 11q23 translocations.

Authors:  Y Kaneko; N Maseki; N Takasaki; M Sakurai; Y Hayashi; S Nakazawa; T Mori; M Sakurai; T Takeda; T Shikano
Journal:  Blood       Date:  1986-02       Impact factor: 22.113

8.  Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.

Authors:  C Biernaux; M Loos; A Sels; G Huez; P Stryckmans
Journal:  Blood       Date:  1995-10-15       Impact factor: 22.113

9.  The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.

Authors:  S Bose; M Deininger; J Gora-Tybor; J M Goldman; J V Melo
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

10.  ALL-1 partial duplication in acute leukemia.

Authors:  S A Schichman; M A Caligiuri; Y Gu; M P Strout; E Canaani; C D Bloomfield; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

View more
  16 in total

Review 1.  RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.

Authors:  James K Mangan; Nancy A Speck
Journal:  Crit Rev Oncog       Date:  2011

Review 2.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

3.  Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation.

Authors:  Coline Gaillard; Taku A Tokuyasu; Galit Rosen; Jason Sotzen; Adeline Vitaliano-Prunier; Ritu Roy; Emmanuelle Passegué; Hugues de Thé; Maria E Figueroa; Scott C Kogan
Journal:  Haematologica       Date:  2015-06-18       Impact factor: 9.941

Review 4.  Unveiling Human Non-Random Genome Editing Mechanisms Activated in Response to Chronic Environmental Changes: I. Where Might These Mechanisms Come from and What Might They Have Led To?

Authors:  Loris Zamai
Journal:  Cells       Date:  2020-10-27       Impact factor: 6.600

Review 5.  Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.

Authors:  Gerald B W Wertheim; Elizabeth Hexner; Adam Bagg
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

Review 6.  Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?

Authors:  Federico Mosna; Debora Capelli; Michele Gottardi
Journal:  J Clin Med       Date:  2017-06-03       Impact factor: 4.241

7.  Incidence of common preleukemic gene fusions in umbilical cord blood in Slovak population.

Authors:  Milan Škorvaga; Ekaterina Nikitina; Miroslav Kubeš; Pavol Košík; Beata Gajdošechová; Michaela Leitnerová; Lucia Copáková; Igor Belyaev
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

Review 8.  The epigenetic landscape of acute myeloid leukemia.

Authors:  Emma Conway O'Brien; Steven Prideaux; Timothy Chevassut
Journal:  Adv Hematol       Date:  2014-03-23

9.  Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies.

Authors:  Lucas Swanson; Gordon Robertson; Karen L Mungall; Yaron S Butterfield; Readman Chiu; Richard D Corbett; T Roderick Docking; Donna Hogge; Shaun D Jackman; Richard A Moore; Andrew J Mungall; Ka Ming Nip; Jeremy D K Parker; Jenny Qing Qian; Anthony Raymond; Sandy Sung; Angela Tam; Nina Thiessen; Richard Varhol; Sherry Wang; Deniz Yorukoglu; Yongjun Zhao; Pamela A Hoodless; S Cenk Sahinalp; Aly Karsan; Inanc Birol
Journal:  BMC Genomics       Date:  2013-08-14       Impact factor: 3.969

10.  Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors.

Authors:  C Wichmann; I Quagliano-Lo Coco; Ö Yildiz; L Chen-Wichmann; H Weber; T Syzonenko; C Döring; C Brendel; K Ponnusamy; A Kinner; C Brandts; R Henschler; M Grez
Journal:  Leukemia       Date:  2014-06-04       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.